President Joe Biden’s 2024 budget proposal and the Limit, Save, Grow Act of 2023 that was passed by the House last month will have a chilling effect on biomedical research, members of the Senate Appropriations Labor, Health and Human Services, and Education Subcommittee said at a hearing May 4.
Undeterred by NIH’s failure to address a set of questions submitted seven months ago, a House oversight committee is persisting with its investigation into handling of sexual harassment complaints at institutions that receive federal funding.
NIH and NCI received a $2.5 billion and $408 million increase, respectively, in the fiscal year 2023 omnibus appropriations package that President Joe Biden signed into law Dec. 23.
The 2024 Bypass Budget submitted by NCI Acting Director Douglas Lowy asks for $9.988 billion—$2.222 billion more than the 2023 document submitted by then director Ned Sharpless.
A House committee is requesting that NIH provide answers to 30 questions about the “pervasive culture of sexual harassment” in biomedical research.
NIH is now required by law to direct grantee institutions to report senior personnel who are disciplined for misconduct, sexual or otherwise.
Effective July 9, NIH-funded institutions that do not report relevant cases of misconduct—including sexual harassment, bullying, and retaliation—within one month would be considered to be in violation of NIH regulations and of federal law.
The House of Representatives on June 22 voted 336-85 to pass legislation that would establish the authorities of the Advanced Research Projects Agency-Health (ARPA-H), President Joe Biden’s proposed high-risk, high-reward biomedical research agency.
In a letter addressed to FDA Commissioner Robert Califf, Republican leaders of the House Committee on Energy and Commerce and two of its subcommittees raised questions about the increasing number of clinical trials conducted in China by companies seeking FDA approval for “me-too” checkpoint inhibitor drugs.
In testimony before the House Labor HHS Appropriations Subcommittee May 26, cancer organizations recommended FY23 appropriations of $49 billion for NIH, $7.76 billion for NCI, and $426.6 million for the CDC’s Division of Cancer Prevention and Control.
